Table 1.
Study characteristics.
| Nelson et al. (17): | Kumar et al. (16): | Gomez-Lobo et al. (15): | |
|---|---|---|---|
| Publication year: | 2016 | 2013 | 2014 |
| Nation: | USA | Canada | USA |
| Number of hospitals or centres: | Two | One | Two |
| Vaccine type: | Quadrivalent HPV vaccinea | Quadrivalent HPV vaccinea | Quadrivalent HPV vaccinea |
| Methods of measuring: | IgG cLIA and cLIA | IgG ELISA and cLIA | cLIA |
| Participants: | n = 23b | n = 47c | n = 17d |
| Sex (n): | Females (23) | Females (31) | Not specified |
| Males (16) | |||
| Age range in years: | 11- 21 | 18 - 35 | 11-19 |
| Type of organ transplant (n): | Kidney (23) | Kidney (30) | Kidney (14) |
| Liver (1) | Liver (3) | ||
| Lung (11) | |||
| Heart (3) | |||
| Heart-lung / multivisceral (2) |
cLIA; competitive Luminex Immunoassay, IgG cLIA; Immunoglobulin G competitive Luminex Immunoassay, IgG ELISA; Immunoglobulin G enzyme-linked immunosorbent assay.
The quadrivalent HPV vaccine was given at month 0, month 2 and month 6.
Nelson et al.(17) enrolled 67 patients, 57 patients completed the three-dose vaccine series and had at least one blood draw after vaccination. Of these 57 patients; 25 had chronic kidney disease, nine were dialysis patients and 23 were kidney transplant recipients.
Kumar et al.(16) enrolled 50 patients, two patients did not receive any doses of the vaccine and one was found to have a prior history of low-grade squamous lesion. These three patients were excluded, while n = 47 continued in the study.
Gomez-Lobo et al.(15) enrolled 25 liver and kidney transplant recipients, of these 17 patients fulfilled criteria to start vaccination.